897 related articles for article (PubMed ID: 23216746)
1. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
[TBL] [Abstract][Full Text] [Related]
2. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B; Bonnard C; Renard E
Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
[TBL] [Abstract][Full Text] [Related]
3. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
4. Incretin-based therapies and cardiovascular risk.
Mannucci E; Dicembrini I
Curr Med Res Opin; 2012 May; 28(5):715-21. PubMed ID: 22439700
[TBL] [Abstract][Full Text] [Related]
5. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular effects of incretins in diabetes.
Advani A; Bugyei-Twum A; Connelly KA
Can J Diabetes; 2013 Oct; 37(5):309-14. PubMed ID: 24500557
[TBL] [Abstract][Full Text] [Related]
7. Impact of glucagon-like peptide-1 on endothelial function.
Sjöholm A
Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():19-25. PubMed ID: 19878258
[TBL] [Abstract][Full Text] [Related]
8. Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes.
Cariou B
Diabetes Metab; 2012 Oct; 38(4):298-308. PubMed ID: 22672960
[TBL] [Abstract][Full Text] [Related]
9. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
van Genugten RE; van Raalte DH; Diamant M
Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.
Anagnostis P; Athyros VG; Adamidou F; Panagiotou A; Kita M; Karagiannis A; Mikhailidis DP
Diabetes Obes Metab; 2011 Apr; 13(4):302-12. PubMed ID: 21205117
[TBL] [Abstract][Full Text] [Related]
11. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
12. Incretin-based therapies: therapeutic rationale and pharmacological promise for type 2 diabetes.
Wick A; Newlin K
J Am Acad Nurse Pract; 2009 Nov; 21 Suppl 1():623-30. PubMed ID: 19900193
[TBL] [Abstract][Full Text] [Related]
13. Differentiating incretin-based therapies for population-based health care.
Calabrese D
Am J Manag Care; 2011 Mar; 17(2 Suppl):S52-8. PubMed ID: 21517657
[TBL] [Abstract][Full Text] [Related]
14. Incretin therapy and its effect on body weight in patients with diabetes.
Lind M
Prim Care Diabetes; 2012 Oct; 6(3):187-91. PubMed ID: 22613745
[TBL] [Abstract][Full Text] [Related]
15. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Gallwitz B
Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes?
Burgmaier M; Heinrich C; Marx N
Diabet Med; 2013 Mar; 30(3):289-99. PubMed ID: 22804451
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials.
Balakumar P; Dhanaraj SA
Cell Signal; 2013 Sep; 25(9):1799-803. PubMed ID: 23707531
[TBL] [Abstract][Full Text] [Related]
18. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
19. Is there a place for incretin therapies in obesity and prediabetes?
Holst JJ; Deacon CF
Trends Endocrinol Metab; 2013 Mar; 24(3):145-52. PubMed ID: 23415157
[TBL] [Abstract][Full Text] [Related]
20. Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus.
Davidson MH
Postgrad Med; 2014 May; 126(3):56-65. PubMed ID: 24918792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]